### A Landmark Partnership in the Cannabis Industry
SOMAÍ Pharmaceuticals, a frontrunner in the European Union Good Manufacturing Practice (EU-GMP) landscape, has forged an exciting partnership with Pacific Cannovation Company Limited (PACCAN). This collaboration aims to position Thailand as a global hub for high-quality medicinal cannabis. Through this synergy, SOMAÍ merges its global distribution acumen with PACCAN’s esteemed leadership in Thailand, establishing a stronghold in the burgeoning cannabis market.
### Thailand: The Rising Star of Medicinal Cannabis
Thailand is on the cusp of becoming Asia’s most dynamic medicinal cannabis market. With projections estimating internal sales to hit $1 billion by 2024, the timing for this collaboration could not be better. SOMAÍ leverages its extensive experience in navigating complex regulatory landscapes to ensure that only premium, EU-GMP-certified products are accessible to patients across Europe, the UK, and beyond. Meanwhile, PACCAN, a pioneer in plant-based biotechnology, stands as a testament to Thailand’s commitment to ethical and responsible cannabis production, ensuring adherence to the highest medical standards.
### Defining a Cross-Continental Powerhouse
The partnership fortifies Thailand’s position as the epicenter of cannabis in Asia, seamlessly integrating its offerings into SOMAÍ’s extensive global distribution network, which spans 12 countries and continues to grow. Within this partnership, SOMAÍ will exclusively represent PACCAN’s products in Europe and the Rest of the World (ROW), while PACCAN will reciprocate by representing SOMAÍ in Asia.
### Comprehensive Product Development and Distribution
The agreement encompasses the distribution of various medicinal cannabis products, including flowers and extracts, while also laying the groundwork for future product development and clinical trials. By utilizing SOMAÍ’s exceptional quality assurance, regulatory knowledge, and inventory management capabilities, this partnership aims to deliver unparalleled products to patients worldwide. Notably, SOMAÍ plans to sponsor PACCAN’s state-of-the-art facilities to achieve EU-GMP certification, enhancing the collaborative effort’s strength and ensuring a seamless integration of operations.
### Visionary Statements from Leadership
Michael Sassano, CEO of SOMAÍ Pharmaceuticals, articulates the essence of this collaboration: “Our partnership is about setting a new global standard, where two unique companies from different continents share and leverage each other’s strengths for mutual benefit. Together with PACCAN, we’re showcasing that Thai medicinal cannabis can stand on par with the best globally, while also affirming that European products can thrive in Asian markets. This is not merely a business venture; it’s a commitment to collaboration, shared values, and the best outcomes for patients worldwide.”
Meanwhile, Joe Trairatanobhas, CEO of PACCAN, emphasizes the significance of this partnership for their entry into the global medical cannabis arena. He states, “SOMAÍ’s established global distribution network synergizes perfectly with our strong presence in Asia, enabling us to create an efficient medical cannabis platform. As we see Asia’s rapidly aging population, it’s vital that we introduce high-quality products to global markets. This partnership is not just about the present; it lays the groundwork for future innovations in herbal medicines, extending beyond just cannabis.”
### Recognition from Leaders
Suppachai Jaisamut, an advisor to several Thai governmental ministries and a former chairman of the National Cannabis Committee, expressed his enthusiasm for this partnership. “With SOMAÍ, the potential for high-quality, legal Thai products to make their mark internationally is immense,” he notes. Jaisamut views the collaboration as pivotal for the Thai medical cannabis industry, asserting that under Sassano’s guidance, it will finally take its rightful place on the global stage. His encouragement reflects a significant consensus around the potential for this partnership to spur growth in the industry.
### Looking Ahead: The Future of Medicinal Cannabis
With Thailand poised to enact the Cannabis Act by March 2025, the nation is set to become a focal point for plant-based medicines throughout Asia. SOMAÍ and PACCAN are at the forefront of this revolutionary shift, merging innovation, quality assurance, and ethical practices to elevate the entire industry.
Together, they are not just partners; they’re pioneers setting the stage for a global cannabis superhighway that connects Asia and Europe through shared expertise, innovative solutions, and a unwavering commitment to excellence.